C012 | NOVEL ANALYSIS OF RESULTS FROM THE PIVOTAL EPCORE NHL-1 STUDY: OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AND COMPLETE RESPONSE AT 2-YEARS WITH EPCORITAMAB MONOTHERAPY

Background: Depth and duration of CR correlate with long-term outcomes in LBCL. Epcor is a subcutaneous CD3xCD20 bispecific antibody approved for the treatment (tx) of pts with DLBCL or high-grade BCL after ≥2 lines of tx (LOT). In the 3-y follow-up (FU) from NHL-1 (NCT03625037), epcor led to durab...

Celý popis

Podrobná bibliografie

Hlavní autoři:	P.L. Zinzani, Y. H. Karimi, J.M. Vose, M. Roost Clausen, D. Cunningham, U. Farooq, T. Feldman, H. Ghesquieres, W. Jurczak, K.M. Linton, T. Phillips, W.S. Kim, P. Jafarinasabian, M. Geybels, D. Soong, B. D. Månsson, C. W. Eskelund, M. Atiya, M. Hutchings, C. Thieblemont, C.Y. Cheah
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Ferrata Storti Foundation 2025-09-01
Edice:	Haematologica
On-line přístup:	https://haematologica.org/article/view/12876
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!